Quantcast

Latest metastatic melanoma Stories

2014-10-22 23:14:04

RadioMedix, Inc., a Houston-based biotechnology company and Viewpoint Molecular Targeting LLC of Iowa City were awarded a grant by the Small Business Innovation Research (SBIR) program from the National Cancer Institute. This is a Phase I award for approximately $150,000 that will support the development of novel agents for enhanced targeted imaging and alpha-particle therapy of metastatic melanoma. HOUSTON, TX. (PRWEB) October 22, 2014 Heterogeneity and drug resistance of metastatic...

2014-05-31 08:21:17

Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that data from the PROCLAIM(SM) national patient registry retrospective cohort document an improvement in median overall survival (OS) in patients with metastatic melanoma who were treated with high-dose Proleukin(®) (aldesleukin) as compared to...

2014-04-07 08:29:25

CALGARY, April 7, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that research collaborators will make two poster presentations at the American Association for Cancer Research 2014 Annual Meeting. The Meeting is being held from April 6(th) to 9(th), 2014 in San Diego, CA. "The data presented by these collaborators is contributing to our evolving understanding of how REOLSYIN(®) works, what biomarkers may be predictive of improved...

2014-01-28 16:25:04

DURHAM, N.C. and ALISO VIEJO, Calif., Jan. 28, 2014 /PRNewswire/ -- bioMerieux, Inc. and Clarient, a GE Healthcare Company today announced that bioMerieux's molecular diagnostic test THxID®-BRAF has been added to the service offerings provided by Clarient. Clarient will use THxID® BRAF in order to aid oncologists in selecting metastatic melanoma patients whose tumors carry the BRAF V600E mutation for possible treatment with GlaxoSmithKline's (GSK) Tafinlar® (dabrafenib) as well as...

2013-04-17 15:19:23

Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy. With the hope of predicting patient survival, researchers at the University of Mississippi Medical Center in Jackson and at the Ohio State University Comprehensive Cancer Center in Columbus analyzed CT images and clinical data from 46 patients with metastatic melanoma that were treated...

2012-03-17 00:12:34

Oral BRAF inhibitor can extend survival to 16 months for some patients An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive,...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.